US EditionNorth Liberty-based Steel Therapeutics secures $2M in strategic investment
Summary by Corridor Business Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
North Liberty-based Steel Therapeutics secures $2M in strategic investment
Steel Therapeutics, an early-stage pharmaceutical company based in North Liberty, has closed a $2 million financing round to support development of its lead product, the Fizurex wipe.The funding round was led by a group of new strategic investors and will help the company advance a pivotal toxicology study later this year and prepare for submission of an Investigational New Drug (IND) application.Steel Therapeutics is developing Fizurex, a singl…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
